Nektar Therapeutics' Experimental Drug Rezpeg Shows Promise for Alopecia Patients
Nektar Therapeutics announced that its experimental drug, rezpeg, has shown promising results in promoting hair growth for individuals suffering from severe alopecia areata, an autoimmune condition that targets hair follicles. After a year of treatment, 27% of participants who received either a low or high dose of rezpeg achieved a significant hair growth outcome, defined as having 80% or more of their scalp covered by hair. This outcome, known as SALT Score 20, is comparable or superior to results from Olumiant, a daily pill by Eli Lilly approved for severe alopecia areata, though Olumiant's use is limited by safety concerns. The two drugs have not been directly compared in clinical trials. 
